Zepbound beats Wegovy for weight loss
Digest more
In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S will undo all that progress.